Navigation Links
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
Date:6/7/2008

he combination compared to 6.1 percent with TriLipix 135mg monotherapy.

Patients treated with the combination of TriLipix 135mg and rosuvastatin 20mg had an increase in HDL of 17.6 percent and decrease in triglycerides of 42.4 percent compared to an HDL increase of 12.2 percent and triglyceride decrease of 26.8 percent with rosuvastatin 20mg alone. LDL decreased 37.4 percent with the combination compared to 6.1 percent with TriLipix 135mg monotherapy.

"New treatment options are critical given that a substantial number of patients are not achieving treatment goals for their three key lipids," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. "Abbott has built a robust clinical program to support TriLipix to provide physicians and patients with as much data as possible to help them evaluate this potential new therapy."

About the TriLipix Clinical Trial Program

The efficacy and safety of TriLipix in combination with the three most commonly prescribed statins -- rosuvastatin, atorvastatin and simvastatin -- were evaluated in three randomized, multi-center, double-blind, controlled, 12-week Phase III studies, totaling 2,698 patients with mixed dyslipidemia.

These studies, along with a 52-week long-term safety and efficacy open-label extension study of 1,911 patients, represent the largest program to date examining a fibrate in combination with statins. More than 2,200 patients were treated with TriLipix alone and in combination with statins across these four studies.

The primary data for TriLipix combined with statins were presented at scientific forums earlier this year.

About TriLipix (ABT-335)

TriLipix is an investigational new fenofibric acid molecule, currently in clinical development for treating patients with unhealthy lipid levels, including LDL cholesterol, triglycerides and HDL cholesterol. A New Drug Application (NDA) for TriLipix for use as monotherapy and in comb
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
2. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
3. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
4. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
5. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
6. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
7. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
8. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
11. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... 29, 2014  BC Technical, the nation,s leading non-OEM ... Imaging, a leader in sales, service and installation of ... BC Technical to continue to expand their resources and ... CT modalities. "We are committed to ... Alvarez , president and CEO of BC Technical. "We ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4BC Technical Acquires Polaris Medical Imaging 2
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, ... to two American aid workers successfully cured a group of ... report. The drug, ZMapp, prompted recovery in all 18 ... medication until five days after infection. ZMapp even cured ... even hours away from death, said study senior author Gary ...
(Date:9/1/2014)... Monday 1 September 2014: Permanent atrial fibrillation (AF) ... according to research in more than 6 000 patients ... from Belgium. The findings suggest that a simple clinical ... to better estimate stroke risk. , Ischaemic stroke is ... for over a million deaths and many more disabled ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... in September, where issues related to claims involving the ... of Pennsylvania, Bernstein Liebhard LLP reports. , According ... Court’s website, the meeting is scheduled to take place ... the latest of several Tylenol conferences that have taken ...
Breaking Medicine News(10 mins):Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4
... you,re ready to drive again , , WEDNESDAY, Dec. 10 (HealthDay ... wheel again after orthopedic surgery or injury, but knowing when it,s ... , Orthopedic surgeons weigh in on the issue in the December ... , "Deciding when a patient can return to driving is ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Inc., a leading,provider of software and databases for systems ... Singapore Immunology Network (SIgN) has become a,certified GeneGo Center ... MetaCore, training and advanced support. SIgN COE will ... "We are excited ...
... Facilities , , NEW ... process, a proven commitment to clinical quality earned SigmaCare(R) ... Metropolitan Jewish Health System,s (Metropolitan) skilled nursing facilities. ... nationally recognized nonprofit organization, operates Metropolitan Jewish Geriatric Center, ...
... Pharma Services, Goodwill, , , ... NYSE: MDZ ), a leading provider of products and ... fiscal 2008 performance. , Based on preliminary information, MDS ... of $1,210 million to $1,220 million and adjusted EBITDA in the ...
... Care Insurance While They,re Still Healthy Enough to Qualify , ... If you,ve put off getting long term care insurance, ... new administration,s health plan? "I wouldn,t advise it," says Denise ... (LTCFP), one of the nation,s most experienced long term care ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... the widest offering of single-use instruments on the ... 43cm lengths for Bariatric Surgery. , Dual ... insulation covers the pivot points to reduce the ... 4mm universal cord, which eliminates gapping at connection ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Medicine Products: